Cargando…

CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping

Cancer subtypes can improve our understanding of cancer, and suggest more precise treatment for patients. Multi-omics molecular data can characterize cancers at different levels. Up to now, many computational methods that integrate multi-omics data for cancer subtyping have been proposed. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Ran, Gao, Lin, Xu, Han, Song, Kuo, Hu, Yuxuan, Wang, Hongda, Dong, Yongqiang, Zhang, Chenxing, Jia, Songwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792302/
https://www.ncbi.nlm.nih.gov/pubmed/31649733
http://dx.doi.org/10.3389/fgene.2019.00966
_version_ 1783459120841490432
author Duan, Ran
Gao, Lin
Xu, Han
Song, Kuo
Hu, Yuxuan
Wang, Hongda
Dong, Yongqiang
Zhang, Chenxing
Jia, Songwei
author_facet Duan, Ran
Gao, Lin
Xu, Han
Song, Kuo
Hu, Yuxuan
Wang, Hongda
Dong, Yongqiang
Zhang, Chenxing
Jia, Songwei
author_sort Duan, Ran
collection PubMed
description Cancer subtypes can improve our understanding of cancer, and suggest more precise treatment for patients. Multi-omics molecular data can characterize cancers at different levels. Up to now, many computational methods that integrate multi-omics data for cancer subtyping have been proposed. However, there are no consistent criteria to evaluate the integration methods due to the lack of gold standards (e.g., the number of subtypes in a specific cancer). Since comprehensive evaluation and comparison between different methods serves as a useful tool or guideline for users to select an optimal method for their own purpose, we develop a scalable platform, CEPICS, for comprehensively evaluating and comparing multi-omics data integration methods in cancer subtyping. Given a user-specified maximum number of subtypes, k-max, CEPICS provides (1) cancer subtyping results using up to five built-in state-of-the-art integration methods under the number of subtypes from two to k-max, (2) a report including the evaluation of each user-selected method and comparisons across them using clustering performance metrics and clinical survival analysis, and (3) an overall analysis of subtyping results by different methods representing a robust cancer subtype prediction for samples. Furthermore, users can upload subtyping results of their own methods to compare with the built-in methods. CEPICS is implemented as an R package and is freely available at https://github.com/GaoLabXDU/CEPICS.
format Online
Article
Text
id pubmed-6792302
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67923022019-10-24 CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping Duan, Ran Gao, Lin Xu, Han Song, Kuo Hu, Yuxuan Wang, Hongda Dong, Yongqiang Zhang, Chenxing Jia, Songwei Front Genet Genetics Cancer subtypes can improve our understanding of cancer, and suggest more precise treatment for patients. Multi-omics molecular data can characterize cancers at different levels. Up to now, many computational methods that integrate multi-omics data for cancer subtyping have been proposed. However, there are no consistent criteria to evaluate the integration methods due to the lack of gold standards (e.g., the number of subtypes in a specific cancer). Since comprehensive evaluation and comparison between different methods serves as a useful tool or guideline for users to select an optimal method for their own purpose, we develop a scalable platform, CEPICS, for comprehensively evaluating and comparing multi-omics data integration methods in cancer subtyping. Given a user-specified maximum number of subtypes, k-max, CEPICS provides (1) cancer subtyping results using up to five built-in state-of-the-art integration methods under the number of subtypes from two to k-max, (2) a report including the evaluation of each user-selected method and comparisons across them using clustering performance metrics and clinical survival analysis, and (3) an overall analysis of subtyping results by different methods representing a robust cancer subtype prediction for samples. Furthermore, users can upload subtyping results of their own methods to compare with the built-in methods. CEPICS is implemented as an R package and is freely available at https://github.com/GaoLabXDU/CEPICS. Frontiers Media S.A. 2019-10-08 /pmc/articles/PMC6792302/ /pubmed/31649733 http://dx.doi.org/10.3389/fgene.2019.00966 Text en Copyright © 2019 Duan, Gao, Xu, Song, Hu, Wang, Dong, Zhang and Jia http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Duan, Ran
Gao, Lin
Xu, Han
Song, Kuo
Hu, Yuxuan
Wang, Hongda
Dong, Yongqiang
Zhang, Chenxing
Jia, Songwei
CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping
title CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping
title_full CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping
title_fullStr CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping
title_full_unstemmed CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping
title_short CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping
title_sort cepics: a comparison and evaluation platform for integration methods in cancer subtyping
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792302/
https://www.ncbi.nlm.nih.gov/pubmed/31649733
http://dx.doi.org/10.3389/fgene.2019.00966
work_keys_str_mv AT duanran cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping
AT gaolin cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping
AT xuhan cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping
AT songkuo cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping
AT huyuxuan cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping
AT wanghongda cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping
AT dongyongqiang cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping
AT zhangchenxing cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping
AT jiasongwei cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping